Galmed Pharmaceuticals Files 6-K Report

Ticker: GLMD · Form: 6-K · Filed: Apr 9, 2026 · CIK: 0001595353

Galmed Pharmaceuticals LTD. 6-K Filing Summary
FieldDetail
CompanyGalmed Pharmaceuticals LTD. (GLMD)
Form Type6-K
Filed DateApr 9, 2026
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: foreign-issuer, disclosure, routine-filing

TL;DR

Galmed Pharma filed a 6-K on 4/9/26, standard foreign issuer report.

AI Summary

Galmed Pharmaceuticals Ltd. filed a Form 6-K on April 9, 2026, reporting information as a foreign issuer. The filing includes standard documents like the 6-K form itself and an exhibit (EX-99.1). The company's mailing and business addresses are listed as C/O MEITAR LAW OFFICES in Ramat Gan, Israel.

Why It Matters

This filing provides routine updates for Galmed Pharmaceuticals Ltd. as a foreign issuer, which is important for investors tracking the company's compliance and disclosures.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign issuer and does not appear to contain significant new financial or operational information.

Key Players & Entities

FAQ

What type of SEC filing is this?

This is a Form 6-K, which is a report of a foreign issuer.

When was this filing made?

The filing date was April 9, 2026.

Who is the filer of this document?

The filer is Galmed Pharmaceuticals Ltd.

What are the listed addresses for Galmed Pharmaceuticals Ltd. in this filing?

The mailing and business addresses are both listed as C/O MEITAR LAW OFFICES, 16 ABBA HILLEL SILVER RD., RAMAT GAN L3 5250608.

What are the document types included in this filing?

The filing includes the 6-K form itself and an exhibit labeled EX-99.1.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on April 9, 2026 regarding Galmed Pharmaceuticals Ltd. (GLMD).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing